8-year relapse-free survival was 62 % ( 95 % CI 55-69 ) in the ADT plus docetaxel and estramustine group versus 50 % ( 44-57 ) in the ADT only group ( adjusted hazard ratio [ HR ] 071 , 95 % CI 054-094 , p = 0017 ) .